, Tracking Stock Market Picks
Enter Symbol:
Catalyst Pharmaceutical Partners, Inc. (CPRX) [hlAlert]

up 632.00 %

Catalyst Pharmaceutical Partners, Inc. (CPRX) rated Buy with price target $5.50 by Aegis Capital

Posted on: Monday,  Oct 21, 2013  10:25 AM ET by Aegis Capital

Aegis Capital rated Buy Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX) on 10/21/2013. Previously Aegis Capital rated Buy Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX)
on 04/18/2013., when the stock price was $0.50. Since then, Catalyst Pharmaceutical Partners, Inc. has gained 632.00% as of 01/22/2016's recent price of $3.66.
If you would have followed the previous Aegis Capital's recommendation on CPRX, you would have gained 632% of your investment in 1009 days.

Catalyst Pharmaceutical Partners, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive-compulsive disorders. Its product candidate CPP-109, which is the version of the chemical compound gamma-vinyl-GABA, referred to as vigabatrin. As of December 31, 2008, the Company was conducting two clinical trials of CPP-109, one evaluating its use in the treatment of cocaine addiction, and a second evaluating its use in the treatment of methamphetamine addiction. CPP-109 has the potential to treat other addictions, including addictions to nicotine, prescription pain, medications, alcohol, and marijuana, as well as obsessive-compulsive disorders, such as obesity and compulsive gambling.

Aegis Capital
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/21/2013 10:25 AM Buy
1.89 5.50
as of 12/13/2013
1 Week down  -0.51 %
1 Month up  45.45 %
3 Months down  -20.98 %
1 YTD up  1.58 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/6/2013 9:25 AM Buy
1.93 4.00
4/18/2013 9:25 AM Buy
0.50 2.50

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy